Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Malignant Hypertension Mimicking Pulmonary-Renal Syndrome

Lee SM, Martinez AF, Yee N. Malignant Hypertension Mimicking Pulmonary-Renal Syndrome. Cureus. 2025 Mar 16;17(3):e80654. doi: 10.7759/cureus.80654. PMID: 40236351; PMCID: PMC11998615.

Association of Texas Nursing Home Non-COVID-19 Mortality Following Winter Storm Uri: A Mixed-Effects Spline Analysis

Frochen S, Saliba D, Dobalian A. Association of Texas Nursing Home Non-COVID-19 Mortality Following Winter Storm Uri: A Mixed-Effects Spline Analysis. Disaster Med Public Health[...]

Genetic Testing Referral Rates for Pheochromocytoma and Paraganglioma in an Academic Tertiary Centre

Ruhle B, Kim NE, Ngo S, Hughes EG, Sajed DP, Yu R, Wu JX, Yeh MW, Livhits MJ. Genetic Testing Referral Rates for Pheochromocytoma and[...]